Open AccessEffect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases
Author(s) -
Hongming Zhu,
Yan Li,
Bangyi Li,
Shuang Yang,
Pingyu Ding,
Xiaojiao Yang,
Xuelian Sun,
Mei Zhang
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i23.5952
Subject(s) - medicine , methylprednisolone , glucocorticoid , retrospective cohort study , cytokine storm , covid-19 , disease , infectious disease (medical specialty)
The coronavirus disease 2019 (COVID-19) outbreak has brought great challenges to public health. Aggravation of COVID-19 is closely related to the secondary systemic inflammatory response. Glucocorticoids are used to control severe diseases caused by the cytokine storm, owing to their anti-inflammatory effects. However, glucocorticoids are a double-edged sword, as the use of large doses has the potential risk of secondary infection and long-term serious complications, and may prolong virus clearance time. Nonetheless, the risks and benefits of glucocorticoid adjuvant therapy for COVID-19 are inconclusive.